dr. martins on managing toxicities associated with lenvatinib in dtc
Published 8 years ago • 521 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
0:48
dr. cabanillas on lenvatinib as first-line therapy for patients with dtc
-
1:17
dr. marcia brose discusses lenvatinib as a new option in dtc
-
1:46
dr. bible on impact of lenvatinib on treatment landscape of dtc
-
1:28
dr. wirth on the use of lenvatinib in hypertensive patients with thyroid cancer
-
1:59
dr. frakes on managing late toxicities associated with treatment for hpv oropharyngeal scc
-
6:27
nccn guidelines for first-line treatment of rr-dtc
-
0:57
dr. taylor discusses the toxicities and impact of lenvatinib in the select trial
-
2:47
dr. brose discusses lenvatinib and sorafenib in differentiated thyroid cancer
-
1:10
dr. marcia brose on lenvatinib in differentiated thyroid cancer
-
9:03
sequencing therapies for differentiated thyroid cancer
-
6:47
lenvatinib: new kid on the block
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
8:28
lenvatinib in advanced dtc
-
1:31
dr. martins on patient selection for nivolumab in nsclc
-
1:00:47
optimizing treatment in differentiated thyroid cancer with dr. newbold
-
2:07
dr. wirth discusses the safety profile of lenvatinib as seen in the select trial
-
1:22
dr. cheng on phase iii findings of lenvatinib in hcc
-
1:14
dr. larkin on lenvatinib plus everolimus in patients with rcc
-
1:39
dr. bastholt on lenvatinib in thyroid cancer